In their recent article in the Journal ( 1 ), Karrison et al. outline a number of possible advantages of reporting response as a continuous variable (percent change in tumor size) rather than as a dichotomous variable. We agree with them as to the value of reporting response as a continuous variable and would like to suggest some additional possible uses of this approach. We have proposed that plotting percent change in tumor size versus treatment dose might offer increased insight into dose -response relationships and that this might be used to infer predominant resistance mechanisms ( 2 ) . Furthermore, the relationship of change in tumor size versus dose with the first cycle of therapy may reflect intrinsic resistance mechanisms, whereas the relationship to dose of further change in tumor size with later cycles of therapy may suggest how acquired resistance differs from intrinsic resistance ( 2 ). To infer potential major resistance mechanisms, we have used estimated percent tumor cell killing derived from published response rates in assessments of dose -response relationships in non -small cell lung cancer, but we feel that use of percent change in tumor size in individual patients would be preferable if such information were available ( 3 ). We have also found that it is feasible to use percent further change in tumor size with each subsequent cycle of therapy to assess the individual impact of each of the four regimens used in a randomized alternating strategy to treat non -small cell lung cancer ( 4 ). DAVID J . STEWART
